Eversense 365 is said to be the world's first one-year CGM system, offering a new long-term solution for diabetes management.

Senseonics (NYSE:SENS) announced today that it received FDA clearance for its next-generation Eversense 365 CGM system.

Senseonics Holdings Inc (SENS) stock saw a decline, ending the day at $0.41 which represents a decrease of $-0.03 or -6.82% from the prior close of $0.44. The stock opened at $0.49 and touched a low ...

After collecting FDA green lights for 90- and 180-day versions, the agency has cleared the latest generation of the Eversense ...

GERMANTOWN, Md., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term ...

Senseonics Holdings, Inc. SENS and Mercy, a leading healthcare system based in St. Louis, have inked a collaboration deal to ...

Senseonics Holdings Inc (SENS) stock saw a modest uptick, ending the day at $0.34 which represents a slight increase of $0.02 or 6.25% from the prior close of $0.32. The stock opened at $0.33 and ...

In a report released on September 20, Marie Thibault from BTIG maintained a Buy rating on Masimo (MASI – Research Report), with a price ...

Senseonics has revealed promising results for its Eversense technology, a long-term implantable continuous glucose monitoring (CGM) system. The PRECISE II trial looked at the safety and ...

Senseonics has raised over $40 million to fund the US launch of its Eversense continuous glucose monitor (CGM). Most of the funding has come from major shareholder Roche through its ...

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of ...

Senseonics Holdings, Inc. (NYSE: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with ...